ESMO 2022 | The latest in neo-adjuvant therapy for luminal breast cancer

Nadia Harbeck, MD, PhD, Ludwig Maximilians University, Munich, Germany, provides an overview of guidelines in treating luminal early breast cancer. Neoadjuvant chemotherapy has proven to be safe and effective, especially in patients who would normally receive adjuvant chemotherapy. A gene expression assay conducted in a biopsy sample can determine who is suited for neoadjuvant therapy, as suggested in the Phase II/III ADAPT trial (NCT01779206). For patients with up to three nodes and are an intermediate clinical risk, docetaxel and cyclophosphamide is an option and Prof. Harbeck additionally highlights the utility of neoadjuvant abemaciclib and olaparib. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.